Is It Too Late To Consider Medpace (MEDP) After Its Strong Multi Year Share Price Run

Simply Wall St.

Feb 01

If you are wondering whether Medpace Holdings is still good value after its strong run, you are not alone. This article focuses squarely on what you are paying for each dollar of its business today. ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2608500627"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2608500627\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2608500627?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000","is_english":true,"pubTime":"2026-02-01 09:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2608500627","market":"hk","top_or_hot":-1,"title":"Is It Too Late To Consider Medpace (MEDP) After Its Strong Multi Year Share Price Run","media":"Simply Wall St.","content":"<div>\n<p>If you are wondering whether Medpace Holdings is still good value after its strong run, you are not alone. This article focuses squarely on what you are paying for each dollar of its business today. ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-medp/medpace-holdings/news/is-it-too-late-to-consider-medpace-medp-after-its-strong-mul\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is It Too Late To Consider Medpace (MEDP) After Its Strong Multi Year Share Price Run</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs It Too Late To Consider Medpace (MEDP) After Its Strong Multi Year Share Price Run\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-01 09:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-medp/medpace-holdings/news/is-it-too-late-to-consider-medpace-medp-after-its-strong-mul><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>If you are wondering whether Medpace Holdings is still good value after its strong run, you are not alone. This article focuses squarely on what you are paying for each dollar of its business today. ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-medp/medpace-holdings/news/is-it-too-late-to-consider-medpace-medp-after-its-strong-mul\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"DCF","symbol_name":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-medp/medpace-holdings/news/is-it-too-late-to-consider-medpace-medp-after-its-strong-mul","article_id":"2608500627","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-medp/medpace-holdings/news/is-it-too-late-to-consider-medpace-medp-after-its-strong-mul","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2608500627","pubTimestamp":1769910041,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"If you are wondering whether Medpace Holdings is still good value after its strong run, you are not alone. This article focuses squarely on what you are paying for each dollar of its business today.\nThe stock last closed at US$582.48, with returns of 3.7% over the past 30 days, 2.0% year to date, 66.8% over 1 year and 146.7% over 3 years. These figures naturally raise questions about how much future upside or risk is already reflected in the price.\nRecent news around Medpace has largely...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","BK4585":"ETF&股票定投概念","MEDP":"Medpace Holdings Inc.","BK4588":"碎股","LU2065170008.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) INC","BK4121":"生命科学工具和服务","LU2065171311.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) ACC","LU2065169927.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) ACC","LU2065171402.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) INC"},"translate_title":"在Medpace(MEDP)多年强劲股价上涨之后，现在考虑它是否为时已晚","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DCF":1,"MEDP":1.5},"content_text":"If you are wondering whether Medpace Holdings is still good value after its strong run, you are not alone. This article focuses squarely on what you are paying for each dollar of its business today. The stock last closed at US$582.48, with returns of 3.7% over the past 30 days, 2.0% year to date, 66.8% over 1 year and 146.7% over 3 years. These figures naturally raise questions about how much future upside or risk is already reflected in the price. Recent news around Medpace has largely centered on its position within the contract research space and ongoing attention from investors who follow clinical development service providers. This context helps explain why the market has been actively reassessing what the company might be worth, even over shorter periods. On our valuation framework, Medpace scores 3 out of 6 on key checks. Next we will look at what different valuation methods suggest about that score and finish by talking through an even more practical way to think about its value.  Medpace Holdings delivered 66.8% returns over the last year. See how this stacks up to the rest of the Life Sciences industry. AdvertisementApproach 1: Medpace Holdings Discounted Cash Flow (DCF) Analysis The Discounted Cash Flow model estimates what a business could be worth by projecting its future cash flows and then discounting those back to today’s value. For Medpace Holdings, the model used is a 2 Stage Free Cash Flow to Equity approach, based on cash flows in $. The latest twelve month free cash flow is about $669.7 million. Analysts provide explicit free cash flow estimates out to 2030, with projections such as $629.3 million in 2026 and $965.6 million in 2030. Further years are extrapolated by Simply Wall St using those inputs. Aggregating and discounting these projected cash flows results in an estimated intrinsic value of about $735.19 per share. Compared with the recent share price of US$582.48, the model implies the shares trade at roughly a 20.8% discount, which points to Medpace appearing undervalued on this DCF view. Result: UNDERVALUED Our Discounted Cash Flow (DCF) analysis suggests Medpace Holdings is undervalued by 20.8%. Track this in your watchlist or portfolio, or discover 871 more undervalued stocks based on cash flows. MEDP Discounted Cash Flow as at Feb 2026 Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Medpace Holdings. Approach 2: Medpace Holdings Price vs Earnings For a profitable company like Medpace Holdings, the P/E ratio is a useful way to think about what you are paying for each dollar of current earnings. Investors usually accept a higher P/E when they expect stronger earnings growth or see the business as lower risk, and a lower P/E when they expect slower growth or see more risk. Medpace currently trades on a P/E of 37.90x. That sits close to the Life Sciences industry average of about 37.31x and below the peer group average of 54.73x. On the surface, that suggests the market is pricing Medpace broadly in line with the wider industry and at a discount to some peers. Simply Wall St’s Fair Ratio for Medpace is 24.53x. This is its estimate of what a more typical P/E might look like after factoring in elements such as earnings growth, the industry it operates in, profit margins, market cap and company specific risks. This tailored view can be more informative than a simple comparison with peers or the sector because it adjusts for the company’s own characteristics rather than relying only on broad averages. Comparing the Fair Ratio of 24.53x with the current 37.90x suggests the shares screen as overvalued on this measure. Result: OVERVALUED NasdaqGS:MEDP P/E Ratio as at Feb 2026 P/E ratios tell one story, but what if the real opportunity lies elsewhere? Discover 1420 companies where insiders are betting big on explosive growth. Upgrade Your Decision Making: Choose your Medpace Holdings Narrative Earlier we mentioned that there is an even better way to understand valuation, so let us introduce you to Narratives, which are simply your story about a company tied directly to your own assumptions for fair value, future revenue, earnings and margins. A Narrative connects what you believe about Medpace Holdings, such as its role in contract research and how its business might develop, to a specific financial forecast that then leads to a fair value per share. On Simply Wall St, Narratives are available on the Community page, where millions of investors already use them as an easy tool to compare their fair value to the current share price so they can decide whether Medpace looks attractively priced or expensive on their numbers. Because Narratives on the platform update when new information like earnings releases or major news is added, your Medpace view can stay current without you rebuilding your work from scratch. For example, one Medpace Narrative might assume a relatively conservative fair value while another assumes a much higher fair value, which shows how investors with the same data can reach very different conclusions about what the shares are worth today. Do you think there's more to the story for Medpace Holdings? Head over to our Community to see what others are saying! NasdaqGS:MEDP 1-Year Stock Price Chart  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}